The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index; 49 of the 73 sources its claims cite were checked for support.
Effects of SPI1-mediated transcriptome remodeling on Alzheimer's disease-related phenotypes in mouse models of Aβ amyloidosis
Open accessAbstract
SPI1 was recently reported as a genetic risk factor for Alzheimer's disease (AD) in large-scale genome-wide association studies. However, it is unknown whether SPI1 should be downregulated or increased to have therapeutic benefits. To investigate the effect of modulating SPI1 levels on AD pathogenesis, we performed extensive biochemical, histological, and transcriptomic analyses using both Spi1-knockdown and Spi1-overexpression mouse models. Here, we show that the knockdown of Spi1 expression significantly exacerbates insoluble amyloid-β (Aβ) levels, amyloid plaque deposition, and gliosis. Conversely, overexpression of Spi1 significantly ameliorates these phenotypes and dystrophic neurites. Further mechanistic studies using targeted and single-cell transcriptomics approaches demonstrate that altered Spi1 expression modulates several pathways, such as immune response pathways and complement system. Our data suggest that transcriptional reprogramming by targeting transcription factors, like Spi1, might hold promise as a therapeutic strategy. This approach could potentially expand the current landscape of druggable targets for AD.
Overview
CoChat Summary
## TL;DR
This mouse study tested whether changing Spi1/SPI1 levels alters Alzheimer’s-related amyloid pathology in vivo. Spi1 knockdown worsened Aβ accumulation and gliosis, while Spi1 overexpression reduced amyloid burden, gliosis, and plaque-associated neuritic damage.
## Key findings
- In 4-month-old APP/PS1 mice, Spi1 knockdown increased insoluble Aβ40 and Aβ42 in cortex by 1.71- and 1.48-fold, and in hippocampus by 1.89- and 1.93-fold, respectively.
- Spi1 knockdown also increased amyloid plaque burden by 1.76-fold in cortex and 2.59-fold in hippocampus, and increased fibrillar plaque deposition by 1.56- and 1.59-fold, respectively.
- In 5XFAD mice, Spi1 overexpression decreased insoluble Aβ40 and Aβ42 in cortex by 71.5% and 52.9% in females, and decreased hippocampal Aβ40 and Aβ42 by 29.5% and 22.2%; similar decreases were also observed in males.
- Spi1 overexpression reduced cortical plaque load by 45.3% and 46.8% and fibrillar plaque burden by 55.6% and 60.9% in female cortex and hippocampus, respectively; it also reduced IBA1- and GFAP-positive cortical area by 46.2% and 54.4% and lowered plaque-associated LAMP1 clusters by 36.3% in cortex and 48.0% in hippocampus.
- Targeted transcriptomics found 26 DEGs in Spi1-knockdown APP/PS1 cortex and 43 DEGs in Spi1-overexpression 5XFAD cortex; integrative analyses highlighted immune response and complement-related pathways, including TYROBP-centered and microglial phagocytosis pathways.
- Single-cell RNA-seq of 16,456 filtered cells formed 19 clusters; Spi1 overexpression induced cell-type-specific transcriptional changes, with 16 DEGs in astrocytes, 4 in neurons, and 27 in microglia after a 1.5-fold-change threshold.
## Methods
- The study used two in vivo mouse models: Spi1+/−;APP/PS1 versus Spi1+/+;APP/PS1 at 4 months, and Spi1Tg/0;5XFAD versus Spi1+/+;5XFAD at 4 months; both sexes were used, but APP/PS1 data were combined across sex while 5XFAD analyses were done separately by sex.
- Outcomes were measured with biochemical assays for insoluble Aβ, histology/immunofluorescence for plaques, gliosis, and LAMP1-positive dystrophic neurites, plus NanoString AD panels, qRT-PCR validation, in vitro BV-2 fibrillar Aβ uptake assays, and scRNA-seq from 16,456 QC-passed cells.
- Main analyses included unpaired t-tests, two-way ANOVA with Sidak or Fisher’s LSD post hoc tests, Fisher’s exact test, linear models for NanoString DEGs, enrichment analyses (Enrichr, MetaCore, STRING), and scRNA-seq clustering/annotation with Seurat, scMCA, scWGCNA, and CellChat.
## Limitations
- The paper states that the inverse relationship between the protective SPI1 rs1057233 allele and lower SPI1 expression in peripheral myeloid cells may not directly translate to brain microglia, and says that a mouse model harboring the SPI1 variant would be needed to test loss- versus gain-of-function directly.
- The authors note that their mouse and in vitro findings cannot resolve whether lower SPI1 might be protective at later disease stages; this is stated in the discussion.
- Evident from the text: the study mainly uses 4-month-old mice and focuses on Aβ amyloidosis models, so it does not directly address tau pathology, later disease stages, or human clinical outcomes.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
31 Valid · 3 Not valid · 19 Not checked · 106 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Human genetic studies recently identified SPI1 (encoding PU.1) as a risk factor for Alzheimer’s disease (AD)1–3.”
§ Effects of SPI1-mediated transcriptome remodeling on Alzheimer’s disease-related phenotypes in mouse models of Aβ amyloidosis > Introduction Human genetic studies recently identified SPI1 (encoding PU.1) as a risk factor for Alzheimer’s disease (AD)1–3. PU.1 is a transcription factor that is mainly expressed by myeloid lineage cells, including microglia4,5. In vitro cell culture studies have demonstrated that Spi1 regulates the expression of AD-associated genes involved in the phagocytic activity and immune response of microglia1,6. Because these in vitro systems cannot capture the inherent complexity of the brain and the crosstalk between different cell types, it is unknown how modulation of Spi1 levels may affect AD pathology in vivo. In addition, two somewhat opposing hypotheses have been proposed based on cell culture studies. Earlier studies demonstrated that downregulation of Spi1 in the BV2 microglial cell line decreased the expression of proinflammatory genes while increasing the transcription of genes essential in lipid metabolism1. Because proinflammatory cytokines and dysregulation of lipid metabolism are linked to the pathogenesis of AD, their findings suggest that Spi1-knockdown may have beneficial effects on certain AD pathologies1. On the contrary, Spi1-knockdown also decreases microglial phagocytic activity in vitro, which may lead to an increase in the levels of toxic protein aggregates and dead cell debris1,7. These opposing hypotheses on the roles of Spi1 in microglial activity represent its complex role in AD pathogenesis and the intrinsic difficulty in translating cell culture work into in vivo models. Therefore, it is important to determine the effect of modulating Spi1 levels on AD-related phenotypes under in vivo conditions. In this work, we addressed this knowledge gap by utilizing both Spi1-knockdown and Spi1-overexpression mouse models. We crossbred each mouse model with amyloid-β (Aβ) amyloidosis mouse models to investigate the effects of loss- or gain-of-function of Spi1 on major AD phenotypes in vivo. Our data demonstrate that Spi1 knockdown exacerbates multiple pathological hallmarks, including Aβ aggregation, amyloid plaque accumulation, and gliosis. Conversely, Spi1 overexpression offers significant protection against these phenotypes. To further elucidate the underlying mechanism by which Spi1 regulates AD-related pathology, we utilized targeted and single-cell transcriptomics approaches and found that several immune pathways relevant to AD pathogenesis are regulated by Spi1. Collectively, our findings suggest that activating SPI1 or its downstream pathways may have the potential to protect against Aβ and other pathology.
What the sources say
- Supportedcites [1] Huang, K. L., et al. A common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer’s disease. Nat. Neurosci. 20, 1052–1061 (2017). source
The Discussion identifies SPI1, which encodes PU.1, as the gene responsible for the AD association at the previously reported CELF1 locus. The Results describe genome-wide association and survival analyses linking variants near SPI1 to AD risk and identify SPI1 as the most likely gene underlying that association. (LLM, conf=0.92)
- Supportedcites [2] Kunkle, B. W. et al. Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing. Nat. Genet 51, 414–430 (2019). source
In Candidate gene prioritization at genome-wide loci, the paper includes SPI1 among genes for which evidence indicates an Alzheimer’s disease risk gene at a GWAS locus. The same section reports co-localization of SPI1 expression with disease risk at the SPI1 locus. It does not claim SPI1 was one of this study’s newly identified loci, but the citing sentence does not require that. (LLM, conf=0.90)
- Partly supportedcites [3] Gjoneska, E. et al. Conserved epigenomic signals in mice and humans reveal immune basis of Alzheimer’s disease. Nature 518, 365–369 (2015). sourceExperimental — accuracy not yet measured
The passage labelled Abstract (page not supplied) reports that a large AD genome-wide association signal at the CELF1 locus spans several genes, with its strongest signal upstream of SPI1. It supports an association implicating SPI1, but does not say that the studies identified SPI1 itself unequivocally as the risk gene. (LLM, conf=0.83)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In vitro cell culture studies have demonstrated that Spi1 regulates the expression of AD-associated genes involved in the phagocytic activity and immune response of microglia1,6.”
§ Effects of SPI1-mediated transcriptome remodeling on Alzheimer’s disease-related phenotypes in mouse models of Aβ amyloidosis > Introduction Human genetic studies recently identified SPI1 (encoding PU.1) as a risk factor for Alzheimer’s disease (AD)1–3. PU.1 is a transcription factor that is mainly expressed by myeloid lineage cells, including microglia4,5. In vitro cell culture studies have demonstrated that Spi1 regulates the expression of AD-associated genes involved in the phagocytic activity and immune response of microglia1,6. Because these in vitro systems cannot capture the inherent complexity of the brain and the crosstalk between different cell types, it is unknown how modulation of Spi1 levels may affect AD pathology in vivo. In addition, two somewhat opposing hypotheses have been proposed based on cell culture studies. Earlier studies demonstrated that downregulation of Spi1 in the BV2 microglial cell line decreased the expression of proinflammatory genes while increasing the transcription of genes essential in lipid metabolism1. Because proinflammatory cytokines and dysregulation of lipid metabolism are linked to the pathogenesis of AD, their findings suggest that Spi1-knockdown may have beneficial effects on certain AD pathologies1. On the contrary, Spi1-knockdown also decreases microglial phagocytic activity in vitro, which may lead to an increase in the levels of toxic protein aggregates and dead cell debris1,7. These opposing hypotheses on the roles of Spi1 in microglial activity represent its complex role in AD pathogenesis and the intrinsic difficulty in translating cell culture work into in vivo models. Therefore, it is important to determine the effect of modulating Spi1 levels on AD-related phenotypes under in vivo conditions. In this work, we addressed this knowledge gap by utilizing both Spi1-knockdown and Spi1-overexpression mouse models. We crossbred each mouse model with amyloid-β (Aβ) amyloidosis mouse models to investigate the effects of loss- or gain-of-function of Spi1 on major AD phenotypes in vivo. Our data demonstrate that Spi1 knockdown exacerbates multiple pathological hallmarks, including Aβ aggregation, amyloid plaque accumulation, and gliosis. Conversely, Spi1 overexpression offers significant protection against these phenotypes. To further elucidate the underlying mechanism by which Spi1 regulates AD-related pathology, we utilized targeted and single-cell transcriptomics approaches and found that several immune pathways relevant to AD pathogenesis are regulated by Spi1. Collectively, our findings suggest that activating SPI1 or its downstream pathways may have the potential to protect against Aβ and other pathology.
What the sources say
- Supportedcites [1] Huang, K. L., et al. A common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer’s disease. Nat. Neurosci. 20, 1052–1061 (2017). source
In Results, the authors report that changing Spi1 expression in cultured BV2 microglial cells altered expression of several AD-associated genes. The Discussion links Spi1-responsive genes to phagocytosis and reports changes in inflammatory-response genes after Spi1 knock-down. (LLM, conf=0.93)
- Supportedcites [6] Rustenhoven, J. et al. PU.1 regulates Alzheimer’s disease-associated genes in primary human microglia. Mol. Neurodegener. 13, 44 (2018). source
The Discussion reports that PU.1 silencing in cultured primary human microglia changed genes involved in phagocytosis and innate and adaptive immune functions. The Results identify these as AD-associated microglial genes. The cited study therefore supports the claim about Spi1/PU.1 regulation in vitro. (LLM, conf=0.93)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Consistent with the reported phenotypes of the 5XFAD model17, we found that Aβ accumulation in females was almost double that of males.”
§ Effects of SPI1-mediated transcriptome remodeling on Alzheimer’s disease-related phenotypes in mouse models of Aβ amyloidosis > Results > Overexpression of Spi1 decreases Aβ accumulation and plaque burden
What the sources say
- Partly supportedcites [17] Sadleir, K. R., Eimer, W. A., Cole, S. L. & Vassar, R. Aβ reduction in BACE1 heterozygous null 5XFAD mice is associated with transgenic APP level. Mol. Neurodegener. 10, 1 (2015). sourceExperimental — accuracy not yet measured
The Results section reports higher cerebral Aβ42 levels and more plaques in female than male 5XFAD mice, particularly for the BACE1+/+ genotype. It does not give an almost-twofold female-to-male Aβ comparison in the retrieved passages; the approximately 50% lower values reported for males concern the APP cleavage products sAPPβ and C99, not Aβ42. (LLM, conf=0.84)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A previous report demonstrated no sex-dependent difference in the phenotypes of APP(Swe)/PS1(L166P) mice8.”
§ Effects of SPI1-mediated transcriptome remodeling on Alzheimer’s disease-related phenotypes in mouse models of Aβ amyloidosis > Results > Knockdown of Spi1 increases Aβ aggregation and amyloid deposition
What the sources say
- Partly supportedcites [8] Radde, R. et al. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 7, 940–946 (2006). sourceExperimental — accuracy not yet measured
The Cerebral amyloidosis section reports that Aβ levels and amyloid load in 1- and 2-month-old male APPPS1-21 mice were not statistically different from females. That supports no sex difference in those measured early amyloid outcomes, but the paper says the analysis was mainly restricted to females and does not establish no sex-dependent difference across the mice’s phenotypes. (LLM, conf=0.88)
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Especially, the extent of dystrophic neurite pathology is often used as an important readout of plaque-associated neuronal toxicity23.”
§ Effects of SPI1-mediated transcriptome remodeling on Alzheimer’s disease-related phenotypes in mouse models of Aβ amyloidosis > Results > Decrease in dystrophic neurites by Spi1 overexpression
What the sources say
- Supportedcites [23] Ulrich, J. D. et al. ApoE facilitates the microglial response to amyloid plaque pathology. J. Exp. Med. 215, 1047–1058 (2018). source
In “Increased neuritic dystrophy in Apoe -/-;APP PS1 mice,” the authors assess plaque-associated neuronal toxicity by labeling dystrophic neurites and quantifying them near plaques. The section also discusses earlier studies linking neuritic dystrophy to plaque pathology, supporting its use as a readout. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
105 more claims · 14 with their cited sources checked
Create a free account to see all 159 claims and to verify the 3 references still open.
- Probably not a substantial claim. 28
- It may state two separate claims as one. 26
- The quote only partly states this claim. 3
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Aβ levels↓, Amyloid burden↓, microgliosis↓, astrogliosis↓, dystrophic neurites↓, Aβ phagocytosis↑”
From Targeting Microglial Transcriptional Reprogramming as a Therapy Strategy for Alzheimer's Disease (2026) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Aβ levels↑, Amyloid burden↑, microgliosis↑, astrogliosis↑, Aβ phagocytosis↓”
From Targeting Microglial Transcriptional Reprogramming as a Therapy Strategy for Alzheimer's Disease (2026) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Aβ levels↑, Amyloid burden↑, microgliosis↑, astrogliosis↑, Aβ phagocytosis↓”
From Targeting Microglial Transcriptional Reprogramming as a Therapy Strategy for Alzheimer's Disease (2026) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Aβ levels↑, Amyloid burden↑, microgliosis↑, astrogliosis↑, Aβ phagocytosis↓”
From Targeting Microglial Transcriptional Reprogramming as a Therapy Strategy for Alzheimer's Disease (2026) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“as well as exacerbated microgliosis and astrogliosis in 5XFAD. 25 , 57”
From Unique transcriptomic alterations in 5XFAD;PS19 mouse model identify glial lipid dysregulation and coordinated microglial–oligodendrocyte responses (2026) · cites this paper as [25]
Experimental — accuracy not yet measured
17 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Cytoscape: A software Environment for integrated models of biomolecular interaction networks
Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., & Ideker, T. (2003) · Genome Research · doi:10.1101/gr.1239303 · Cited by 51,888
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458
Integrated analysis of multimodal single-cell data
Hao, Y., Hao, S., Andersen-Nissen, E., Mauck, W. M., Zheng, S., Butler, A., Lee, M. J., Wilk, A. J., Darby, C., Zagar, M., et al. (2020) · doi:10.1101/2020.10.12.335331 · Cited by 15,508
Inference and analysis of cell-cell communication using CellChat
Jin, S., Guerrero-Juarez, C. F., Zhang, L., Chang, I., Ramos, R., Kuan, C.-H., Myung, P., Plikus, M. V., & Nie, Q. (2021) · Nature Communications · doi:10.1038/s41467-021-21246-9 · Cited by 8,409
Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool
Chen, E. Y., Tan, C. M., Kou, Y., Duan, Q., Wang, Z., Meirelles, G. V., Clark, N. R., & Ma’ayan, A. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-128 · Cited by 7,814
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226
A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease
Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, T. K., David, E., Baruch, K., Lara-Astaiso, D., Toth, B., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.018 · Cited by 5,493 · cited 1×
“Furthermore, we compared gene expression across clusters with the disease-associated microglia (DAM) and homeostatic microglia gene list 30 and found that microglial clusters 4, 8, and 10 expressed higher levels of DAM genes and lower levels of homeostatic genes compared to other clusters…”
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 21×
“6b and Supplementary Data 8).”
InfluentialNeuropathological alterations in Alzheimer disease
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345
Cited by
Tate, M., Wijeratne, H. R. S., Kim, B., Philtjens, S., You, Y., Lee, D., Gutierrez, D. A., Sharify, D., Wells, M., Perez‐Cardelo, M., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.14243 · Cited by 21
Self-citationZu, X., Chen, S., Li, Z., Hao, L., Fu, W., Zhang, H., Yin, Z., Wang, Y., & Wang, J. (2025) · Bone Research · doi:10.1038/s41413-025-00421-4 · Cited by 24
Liu, A., Citu, C., Enduru, N., Chen, X., Tung, C.-H., Sinha, T., Sepulveda, S. E., Manuel, A. M., Gorski, D., Fernandes, B. S., et al. (2025) · Science Advances · doi:10.1126/sciadv.adw4917 · Cited by 17
“These findings were consistent with prior evidence that TFs can exhibit context-dependent regulatory effects through recruitment of distinct cofactors and chromatin re-modeling complexes ( 47 , 48 ).”
Xu, Y., Wang, M., Wei, H., Yu, M., & Li, Y. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113946 · Cited by 11
The complement cascade in Alzheimer’s disease: modern implications of an ancient immune protagonist
Papavergi, M.-T., Bathini, P., Singh, B. B., & Lemere, C. A. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00916-y · Cited by 13
“Nonetheless, emerging in vivo evidence suggests that PU.1 modulation alters AD-related phenotypes and immune transcriptomes, including complement pathways, further supporting its role in disease-context regulation [346].”
Metadata
- Authors
- Kim, B., Dabin, L. C., Tate, M. D., Karahan, H., Sharify, A. D., Acri, D. J., Al-Amin, M. M., Philtjens, S., Smith, D. C., Wijeratne, H. R. S., Park, J. H., Jucker, M., & Kim, J.
- Affiliations
- Indiana University Indianapolis (US)
- Indiana University School of Medicine (US)
- Indiana University Bloomington (US)
- German Center for Neurodegenerative Diseases (DE)
- Corresponding author
- Kim, Jungsu
- ORCID
- Venue
- Nature Communications
- Published
- 2024-05-11
- Volume
- 15
- Issue
- 1
- Pages
- 3996-3996
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC11088624
- OpenAlex
- W4396826754
- Semantic Scholar
- 680e47088e230e2a0c1c98ee39e19f945e80908b
- Cited by
- 28
- References
- 53
- Citations by year
- 2026: 7 · 2025: 18 · 2024: 3
- FWCI
- 7.90
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- IUScholarWorks (Indiana University) (submittedVersion, cc-by)
- DZNE Pub (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- U.S. Department of Health & Human Services | NIH | National Institute on Aging (R01AG077829, R01AG071281, R21AG072738, RF1AG074543)
- Alzheimer's Association (AARF-21-852175)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- PU.1, Alzheimer's disease, amyloid-beta, amyloid plaques, gliosis, dystrophic neurites, transcriptome remodeling, transcriptional reprogramming, complement system, immune response, druggable targets, mouse model
- MeSH terms
- Proto-Oncogene Protein Spi-1, Alzheimer Disease, Amyloidosis, Animals, Disease Models, Animal, Male, Mice, Inbred C57BL, Mice, Transgenic, Phenotype, Proto-Oncogene Proteins, Trans-Activators, Amyloid beta-Peptides, Gene Expression Profiling, Mice, Gene Knockdown Techniques, Plaque, Amyloid, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of SPI1-mediated transcriptome remodeling on Alzheimer's disease-related phenotypes in mouse models of Aβ amyloidosis. https://app.cochat.ai/papers/10.1038/s41467-024-48484-x
- The paper
- Kim, B., Dabin, L. C., Tate, M. D., Karahan, H., Sharify, A. D., Acri, D. J., Al-Amin, M. M., Philtjens, S., Smith, D. C., Wijeratne, H. R. S., Park, J. H., Jucker, M., & Kim, J. (2024). Effects of SPI1-mediated transcriptome remodeling on Alzheimer's disease-related phenotypes in mouse models of Aβ amyloidosis. Nature Communications. https://doi.org/10.1038/s41467-024-48484-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.